India–US Trade Deal Secures Lifeline for Affordable Generics – Dr Dilip Surana

Dr Dilip Surana, CMD of Micro Labs Limited, hails tariff shield as a landmark step that strengthens India’s $9 billion pharma exports to the US, meeting nearly half of America’s generic drug demand while easing patient cost burdens.

New Delhi/Washington – The India–US bilateral trade agreement marks a pivotal moment for the pharmaceutical sector, reinforcing India’s position as the backbone of global generic drug supply. With the US accounting for nearly $9 billion in annual imports of Indian pharmaceuticals—primarily affordable, off-patent generics that meet almost half of America’s generic drug demand—the tariff shield ensures continuity of access to life-saving medicines at competitive costs. This development not only strengthens India’s export momentum but also deepens trust in the resilience of its healthcare ecosystem. As regulatory pathways open for American medical technology in India, the partnership promises a balanced exchange of innovation and affordability, setting the stage for a new era of healthcare collaboration.

Dr Dilip Surana, Chairman & Managing Director of Micro Labs Limited said to Pharma Leaders

“The latest trade deal between India and the United States is a landmark in healthcare diplomacy. By safeguarding Indian generic exports from tariff barriers, the agreement recognizes the critical role our industry plays in reducing the cost burden for millions of US patients and payers. India’s pharmaceutical sector has consistently delivered affordable, high-quality medicines, and this decision will further consolidate our position as a trusted global partner. At Micro Labs, we see this as an opportunity to expand our footprint, innovate responsibly, and contribute to a healthier, more inclusive future for both nations.”

Company Profile: Micro Labs Limited

Founded in 1973 and headquartered in Bengaluru, Micro Labs Limited has emerged as one of India’s leading pharmaceutical companies, recognized globally for its commitment to quality, affordability, and innovation. With over five decades of expertise, the company operates across diverse therapeutic segments including cardiology, diabetology, anti-infectives, ophthalmology, neurology, dermatology, and pain management, among others.

Micro Labs is a technology-driven healthcare enterprise, distinguished by:

• Cutting-edge R&D capabilities and automation-driven manufacturing facilities that consistently meet international regulatory standards.
• A robust global presence, with exports spanning more than 50 countries, reinforcing India’s reputation as a trusted supplier of affordable generics.
• A comprehensive brand portfolio, ranking among the top 20 in India’s prescription and sales indices, underscoring its formidable domestic and international market presence.
• Commitment to patient-centric innovation, with a strong pipeline of off-patent generics that significantly reduce healthcare costs worldwide.

The company’s ethos—“Good Health in Every Home”—reflects its mission to deliver high-quality medicines at accessible prices. Its scientific advancements in APIs and formulations have propelled breakthroughs in critical therapies, while its digital initiatives, such as the Micro E-Library, provide medical professionals with cutting-edge resources for patient care and education.

DOLO: A Household Name

The company’s most iconic brand, DOLO-650, has become a trusted household name in India. Widely prescribed for fever and pain relief, DOLO gained immense popularity during the COVID-19 pandemic, when it was among the most prescribed medicines nationwide. With over 350 crore tablets sold since 2020, DOLO cemented Micro Labs’ reputation as a reliable provider of essential, affordable healthcare. Its widespread acceptance across urban and rural India reflects the company’s ability to combine scientific excellence with everyday accessibility.

Under the leadership of Dr Dilip Surana, Chairman & Managing Director, Micro Labs continues to expand its footprint in the United States, India’s largest pharmaceutical export market. With Indian generics meeting nearly 40–50% of US demand, Micro Labs plays a pivotal role in easing the cost burden on American patients and payers, while reinforcing India’s stature as the world’s pharmacy.

Micro Labs Limited stands as a prominent force in India’s pharmaceutical landscape. Generally ranked among the top 20 companies in the domestic formulations market—specifically between 18th and 20th place based on sales—Micro Labs has consistently demonstrated resilience, innovation, and patient-centric growth.

The company’s reputation is anchored by its flagship brand DOLO-650, a trusted household name across India. Widely prescribed for fever and pain management, DOLO has risen to become the 6th largest pharmaceutical brand in India, symbolizing both clinical reliability and consumer trust. Its widespread adoption, particularly during the COVID-19 pandemic, reinforced Micro Labs’ stature as a dependable provider of essential medicines.

Beyond DOLO, Micro Labs maintains a strong presence in pain management, anti-diabetic therapies, and nutrient supplements, commanding a market share of approximately 1.7% in the domestic formulations market. This diversified portfolio ensures the company’s relevance across critical therapeutic areas, while its state-of-the-art R&D facilities and globally compliant manufacturing plants enable it to meet the highest international standards.